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Introduction 
Adrenocortical suppression as a consequence of corti- 
costeroid therapy is a well-known and serious systemic 
adverse effect. Although the risk of adrenocorticai sup- 
pression during the treatment of asthma is greatly 
decreased by administering corticosteroids via the 
inhaled compared with the oral route, some concern 
remains regarding the inhalation of high dosages. 
Other adverse effects that have been linked with corti- 
costeroid use include skin changes (thinning, bruising) 
and cataract formation. Adverse effects in children are 
of particular importance because of the possibility that 
the individual will require many years of long-term 
treatment. This article will summarise the available lit- 
erature regarding the potential for inhaled budesonide 
and beclomethasone dipropionate (BDP) to cause 
adrenal suppression, skin changes and cataracts. 
Adrenocortical Suppression 
Several tests are available to assess adrenocortical 
function. In studies of patients receiving inhaled 
steroids, morning plasma cortisol levels, 24 h urinary 
free cortisol levels and/or a short tetracosactrin test 
(plasma cortisol measured 30 m in following an intra- 
muscular injection of tetracosactrin 250 pg) have been 
used most commonly. 
EXPERIENCE IN ADULTS 
Standard dosage 
The standard dosage for inhaled BDP and budesonide 
is considered to be between 200 and 800 pg daily. Three 
Correspondence should be addressed to: R. G. Dluhy, 
Endocrinology-Hypertension Division, Brigham & Womens 
Hospital, 221 Longwood Avenue, Boston, MA 02115, 
U.S.A. 
This supplement was sponsored by Glaxo Wellcome plc. 
0954-6111/98/92B015+09 $12.00/O 
randomised, cross-over, comparative studies, each 
including 130 asthmatic patients, measured the impact 
of BDP and budesonide, both administered at 400 Kg 
daily, on adrenal function (l-3). In one of the studies, 
morning plasma cortisol levels were slightly lower after 
the 2 week treatment period for each drug (1). In 
another, there was no effect of either inhaled cortico- 
steroid on basal cortisol levels (2), and in the remaining 
study, more increases than decreases in basal cortisol 
levels were found following treatment (3). In two of 
these studies a tetracosactrin test was performed, and 
no significant effect was seen with either drug on the 
tetracosactrin-stimulated cortisol response (l-3). Thus, 
conventional dosages of inhaled BDP and budesonide 
do not appear to blunt adrenal function. 
High dosage 
The results of studies comparing high dosages of 
inhaled budesonide and BDP in adult volunteers and 
asthma patients are provided in Table 1 (4-l 1). Most 
studies reported evidence of adrenal suppression as 
indicated by one or more variables. 
Normal volunteers 
Johansson et al. (4) examined the effects of large single 
evening doses of both oral and inhaled budesonide and 
BDP in a cross-over study. Eight volunteers received 
oral BDP and budesonide 2, 4 and 8 mg. Twelve 
volunteers received, by inhalation, BDP 200, 800 and 
3250 pg and budesonide 200, 800 and 3200 pg. BDP 
produced a larger reduction in plasma cortisol levels, 
measured the following day at 8 a.m., 10 a.m. and 12 
noon, than budesonide. However, there are some possi- 
ble drawbacks with this study. Although cortisol levels 
show great variability and have a wide normal range, 
the investigators reported no absolute values for corti- 
sol or any indication of whether the values were out- 
side the normal range. Significance calculations were 
based on the area under the plasma cortisol-time 
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18 R. G. DLUHY 
curve, although the curve had only three points. 
Lofdahl et al. (5) gave 19 healthy volunteers BDP 
2250 yg inhaled three times daily for 2 days. Of these 
19 individuals, the 12 who had decreases in plasma 
cortisol of ~50% were then entered in a cross-over 
study and received daily doses of BDP 1500, 3000 and 
4500 l.tg and budesonide 2400,480O and 7200 pg daily 
for 2 days. After the lowest dosage of both corti- 
costeroids, serum cortisol levels decreased significantly 
compared with pre-treatment values. The authors 
reported that the dose-response curves were parallel 
but that budesonide was less potent in suppressing 
serum cortisol than BDP The validity of this compar- 
ative study in a population selected for sensitivity to 
adrenal suppression by BDP may be questionable. In 
an open, cross-over study, 39 healthy volunteers 
received 800 or 2500 ltg of budesonide or BDP daily 
for 2 weeks followed by a 2-week wash-out period 
before crossing over to the other treatment (7). There 
was a significantly greater fall in plasma cortisol with 
BDP compared with budesonide, but there were no 
treatment differences in terms of effects on urinary 
cortisol or DHEAS. Both budesonide and BDP had a 
significant dose-related effect on plasma and urinary 
cortisol and DHEAS. A further study by this group con- 
firmed that increasing inhaled dosages of budesonide 
between 800 and 3200 @g daily in volunteers caused 
dose-related decreases in plasma cortisol and adrenal 
cortical androgen levels (12) (data are not shown in 
Table 1 because the study was not comparative). 
Brown et al. (6) conducted a randomised, double- 
dummy, cross-over study in nine healthy adults. BDP 
or budesonide 1000 pg twice daily was administered, 
via a metered dose inhaler (MDI) with or without a 
spacer device, for 6 days and serum cortisol and 24 h 
urinary free cortisol levels were measured. When a 
spacer device was not used, the systemic effects 
observed with BDP (i.e. reductions in serum cortisol 
and 24 h urinary free cortisol levels) were greater than 
with budesonide; however, the use of an MD1 with 
spacer device resulted in no difference for the two 
drugs in the reductions in serum cortisol and 24 h 
urinary free cortisol levels. The magnitudes of the 
changes in serum and urinary cortisol were small with 
both agents (with and without spacer), and the result- 
ing levels remained within the normal range. 
Asthma patients 
Brown et al. (8) carried out a cross-sectional study 
in patients with asthma taking 1200-2650 ug (mean 
1600 ug) daily of an inhaled steroid (BDP, n = 69; 
budesonide, n = 9). Basal morning plasma cortisol and 
24 h urinary free cortisol levels were measured, and a 
short (60 min) tetracosactrin test was performed. If 
two of these three tests were below the normal range, 
the HPA axis was considered to be suppressed. On this 
basis, 16 patients had adrenal suppression (15169 BDP; 
l/9 budesonide). There was no clear relationship 
between adrenal function and the dosage of inhaled 
steroid. A later report by this group of investigators 
rated the relative merits of these three screening tests 
for adrenal suppression (13). The conclusion was that 
the short tetracosactrin test and measurement of 24 h 
urinary free cortisol were equally useful but that 
morning plasma cortisol was a less sensitive screening 
method. 
In a double-blind, double-dummy, cross-over study 
in 36 asthma patients, neither budesonide 800 ng twice 
daily nor BDP 750 ng twice daily for 6 weeks had a 
significant effect on plasma cortisol levels or response 
to the short tetracosactrin test (11). Similarly, an 
earlier randomised, double-blind, cross-over study 
comparing 6-week treatment periods of budesonide 
1600 vg daily via a spacer and BDP 1500 l.tg daily in 
28 patients found no effect of either treatment on the 
short tetracosactrin test (9). However, in this study the 
mean basal cortisol levels were significantly lower after 
both treatments (budesonide P < 0.01; BDP P < O-05), 
but there was no significant between-group difference 
in this parameter after 6 weeks of treatment. 
Selroos and Halme (10) studied the effects of spacer 
devices and mouth rinsing on the systemic absorption 
of budesonide and BDP Three cross-over studies, 
each involving a 2-week treatment period, were con- 
ducted, with morning serum cortisol and 24 h urinary 
free cortisol being measured at the end of each period. 
Study 1 examined 24 patients already taking BDP 
500 ng twice daily (ten using a spacer device) who were 
switched to budesonide dry powder inhaler 600 ng 
twice daily without mouth rinsing. The results showed 
no significant change in serum or urinary cortisol lev- 
els for the patients switching from BDP without a 
spacer. However, a significant drop in levels of both 
parameters was observed in patients switching from 
BDP with a spacer to budesonide dry powder formu- 
lation. A second study, in ten patients taking 
budesonide 800 ug with and without swallowing the 
mouth-rinsing water, showed significantly higher 
serum cortisol levels in patients who mouth rinsed but 
did not swallow. In a third study 17 patients took 
budesonide 800 ng via a dry powder inhaler and BDP 
500 pg via a spacer, both twice daily without mouth 
rinsing. No significant differences were detected in 
serum cortisol levels with either treatment. As 
expected, mouth rinsing with swallowing increased the 
systemic exposure to inhaled steroids but the design of 
this study made it impossible to differentiate the 
effects of the two drugs on adrenal function from the 
effects of the method of administration. 
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Roy et al. (14) found that 14 of 100 patients receiv- 
ing inhaled budesonide or BDP (800-2000 pg daily for 
23 months) had one or more abnormally low results 
for baseline cortisol, 24 h urinary free cortisol or 
response to the tetracosactrin test. Those who had 
more than one abnormal result were more likely to be 
receiving 21500 pg inhaled steroid daily. The study did 
not compare the incidence of abnormal results 
between budesonide and BDP. In a study in asthma 
patients who reported easy bruising after receiving 
inhaled steroids, Melchor et al. (15) found that of 32 
patients receiving a mean dose of 1590 pg day-l only 
two had evidence of adrenal suppression. 
EXPERIENCE IN CHILDREN 
Short-term studies (weeks-monfhs) 
Low to medium dosage 
The results of comparative short-term studies of the 
effect of standard dosages (1400 pg daily) of inhaled 
BDP and budesonide on adrenal function in children 
have been conflicting. In a randomised, double-blind, 
cross-over study in 21 children, Baran (16) found no 
abnormal morning plasma cortisol levels following 
3 weeks of treatment with either budesonide 100 kg 
twice daily or BDP 100 pg twice daily. Similarly, two 
randomised, double-blind, cross-over studies compar- 
ing budesonide 400 pg daily and BDP 400 pg daily for 
4 weeks reported no effect of either agent on adrenal 
function as measured by the tetracosactrin test (17) or 
by 24 h urinary cortisol metabolites (18). However, in 
the study of Springer et al. (18) a subnormal decrease 
in 1 1-deoxycortisol was detected after metyrapone 
challenge in 2/10 children while receiving budesonide 
and in 4/10 children while receiving BDP; cortisol 
responses were variable and adrenocorticotrophic hor- 
mone concentrations increased in most patients (18). 
In a randomised, cross-over study, 12 children received 
budesonide and BDP 400 pg daily, each for 2 weeks 
(19). Both budesonide and BDP significantly sup- 
pressed nocturnal cortisol levels, with the degree of 
suppression being greater after 4 weeks than after 2 
weeks of treatment, regardless of sequence of treatment 
administration. In none of these short-term studies was 
a significant difference in plasma cortisol and in 24 h 
urinary cortisol detected between the two drugs. 
High dosage 
Dosages of inhaled BDP and budesonide >400 pg 
daily in children have been associated with adrenal 
suppression (20). This is supported by evidence from 
Bisgaard et al. (21), who compared budesonide and 
BDP in children with asthma in a randomised, double- 
blind, parallel-group study. Children received daily 
dosages of 200,400 and 800 pg of either BDP (n = 30) 
or budesonide (n = 10) for three consecutive 4-week 
periods. Measurement of 24 h urinary free cortisol 
levels revealed significant dose-related decreases in the 
BDP and budesonide groups, with no significant 
treatment-related difference. There were no significant 
dose- or treatment-related effects for either BDP or 
budesonide according to the tetracosactrin test of 
adrenal function. Similarly, Prahl (22) conducted a 
study comparing BDP and budesonide (500-1800 pg 
daily) for 6-week periods in 16 children with asthma 
and 27 healthy, age- and sex-matched children as con- 
trols. Eleven of the treated children demonstrated no 
difference in 24 h urinary free cortisol with either 
treatment, three individuals had a reproducible 
decrease with BDP and two showed a reproducible 
decrease with budesonide. There was no significant 
difference between the effects of the two drugs. 
In contrast to this observation of no difference in 
effect on adrenal function between the two steroids, a 
randomised, cross-over study comparing budesonide 
with BDP (dosage range 800-1200 pg, mean 900 pg 
day-l) in 3 1 children with asthma found that the reduc- 
tion in 24 h urinary free cortisol was significantly 
greater during the 6-week treatment period with BDP 
compared with budesonide (23). Moreover, this differ- 
ence was greater in children receiving > 1000 pg daily. 
However, most of the 24 h urinary free cortisol values 
of children receiving BDP continued to remain within 
the normal range during treatment. Russel et al. (24) 
conducted a cross-sectional study in children who had 
been receiving daily dosages of 1800 yg and 34 chil- 
dren (2 1 receiving budesonide; 13 receiving BDP) who 
had been receiving dosages >800 pg daily for >3 
months. Adrenal function was assessed by short tetra- 
cosactrin tests. All children receiving 5800 1.18 daily 
had normal basal and stimulated cortisol levels. Some 
children in the >800 pg daily group with both 
treatments had evidence of suppression of either basal 
or stimulated cortisol levels, and four children (two 
receiving BDP and two receiving budesonide) 
had values below the normal reference range for both 
variables. 
Long-ferm studies (21 yr) 
No long-term, comparative studies of the impact of 
inhaled BDP and budesonide on adrenal function in 
children have been published. However, Bhan et al. 
(25) assessed adrenal function in 28 children with 
asthma who had received inhaled BDP for at least 1 yr. 
Eighteen children had previously received pred- 
nisolone and had received BDP (mean 500 pg daily) 
for an average of 3.2 yr, and the remaining ten had not 
received prednisolone but had received BDP (mean 
420 pg daily) for an average of 3.5 yr. These 28 chil- 
dren were compared with 15 children with asthma who 
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had been treated without use of oral or inhaled corti- 
costeroids. Morning cortisol and 24 h urinary free cor- 
tisol levels were measured and short tetracosactrin 
tests were performed. No child showed evidence of 
adrenal suppression. Although mean morning cortisol 
and 24 h urinary free cortisol values were slightly 
lower in children receiving BDP, particularly those 
who had received prior treatment with prednisolone, 
none was considered to be clinically important. 
Varsano et al. (26) conducted an open study in 16 chil- 
dren with severe asthma who had received budesonide 
200 l.rg daily via an MD1 with a spacer for 1 yr. 
Adrenal function was assessed by measuring morning 
plasma cortisol after 1, 3, 6 and 12 months of treat- 
ment and by performing short tetracosactrin tests 
before the study commenced and after 6 and 12 
months of treatment. All individual serum cortisol 
levels were within the normal range at all time points. 
Results of the short tetracosactrin test after 6 and 12 
months of budesonide treatment were also normal. 
Thus, these two long-term, non-comparative studies 
in children with asthma treated for 21 yr with BDP 
(mean 500 pg daily) or budesonide (200 pg daily) found 
no evidence of adrenal suppression with either drug. 
Skin Changes 
The use of systemic corticosteroids has been implicated 
in dermal atrophy, fragility and striae. There is also 
some suggestion that high doses of inhaled corticos- 
teroids can also cause skin changes. In a cross-sectional 
study of 68 patients with moderate to severe asthma, 
Capewell et al. (27) measured skin thickness by ultra- 
sound and clinically assessed purpura. Patients had 
been receiving steroids for up to 30 yr and were divided 
into four groups: those on oral steroids, those on high- 
dose inhaled steroids (BDP 1000-2250 ltg daily), those 
on low-dose inhaled steroids (BDP 200-800 pg daily) 
and controls (who received no steroids). Skin thickness 
was significantly decreased in the oral and the high-dose 
inhaled steroid groups compared with controls; there 
was no difference in thickness between the low-dose 
inhaled steroid group and the control group. The same 
pattern of results was reported for purpura. Because 
patients receiving high-dose inhaled steroids had also 
had a prior exposure to oral steroids (median lifetime 
prednisolone dose of 200 mg), the authors speculated 
that the skin changes in this group could reflect a 
synergistic effect of previous courses of prednisolone. 
Using a questionnaire, Mak et al. (28) found that 
asthma patients taking inhaled steroids (n = 202) had 
more than twice the relative risk of easy bruising com- 
pared with a group of patients of similar age and 
sex distribution who were not using inhaled steroids 
(n = 204). The prevalence of easy bruising appeared to 
be related to increased age, dosage and duration of 
treatment. The two groups were well matched for 
courses of oral corticosteroids taken during the previ- 
ous year but there was no information on the number 
of oral steroid courses before that time. These 
researchers subsequently conducted a prospective, 
open study in asthma patients who had reported easy 
bruising after beginning inhaled steroids (mean dose 
1590 ug day-i) and found that platelet count and 
bleeding times were within the normal ranges (15). 
In agreement with this, in a study of 200 asthma 
patients receiving high-dose inhaled steroids, Roy et al. 
(14) found that twice as many of those receiving high- 
dose inhaled steroids reported skin bruising compared 
with non-asthmatic controls matched for age and sex 
(71% KY. 32% according to questionnaire). There was 
no difference in the incidence of bruising between 
patients receiving BDP and those receiving budes- 
onide (21/73 and 8/27, respectively) but the numbers of 
these patients were too small to allow a meaningful 
comparison. Only 14 patients receiving inhaled 
steroids had one or more test results suggestive of 
impairment of adrenal function. Urinary cortisol lev- 
els, but not blood cortisol levels, were significantly 
higher in patients who did not report skin bruising. In 
addition, older patients (52 years of age) receiving 
inhaled steroids were more likely to report skin bruis- 
ing than elderly patients (61 years of age) not receiving 
inhaled steroids. Unlike the study by Mak et al. (26), a 
dose-response effect was not seen in this study. 
Other skin changes associated with the use of 
inhaled steroids include angina bullosa haemorrhagica 
(oral blood blister) (29,30). In addition, acne has been 
reported in four patients using inhaled corticosteroids 
and it appeared to be dose dependent in one of the 
individuals (31). However, these adverse skin effects 
are very rare. 
Cataract Formation 
Treatment with oral steroids is known to cause 
cataracts of a characteristic appearance, classically 
posterior subcapsular and beginning as a fine, granu- 
lar and vacuolated opacity. The incidence of posterior 
subcapsular cataracts (PSCCs) associated with steroid 
use increases with increased dosage and duration of 
treatment, but there is considerable interindividual 
variation in susceptibility (32). PSCCs have been 
reported to develop following as little as 5 mg pred- 
nisolone daily and in as little as 2 months, although 
the usual time to onset is at least 1 yr with a dosage 
equivalent to prednisolone 10 mg daily. Visual impair- 
ment is usually minimal in PSCCs resulting from 
steroid use, although there have been rare reports of 
cataracts requiring surgical extraction. 
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Toogood et al. (33) studied the association between 
the occurrence of PSCCs and inhaled and oral steroid 
therapy in a cross-sectional study of 48 adults with 
asthma. Twenty-five patients had some type of lens 
opacity, 13 of whom had PSCCs. The occurrence of 
PSCCs correlated with the current daily prednisolone 
dosage and the duration of prednisolone use, but not 
with the dosage or duration of inhaled steroids (mean 
1460 ug daily; mean duration 9.2 yr). 
There have been a number of case reports of asthma 
patients treated with inhaled BDP who subsequently 
developed PSCCs, but almost all of these patients had 
also received oral steroids (3437). 
Sevel et al. (38) studied 42 asthmatic children who 
had received oral corticosteroids for a minimum of 
3 yr. Twelve were treated with inhaled BDP. Only one 
child had cataracts concurrent with corticosteroid 
therapy, and this child was found to be steroid depen- 
dent and markedly growth stunted. Nassif et al. (39) 
performed slit-lamp examination of the eyes of 56 
asthmatic children on steroid therapy followed up for 
at least 6 months. Small, clinically non-apparent, 
subcapsular cataracts were detected in l/24 children 
treated with alternate-day oral prednisolone and in 
l/32 treated with inhaled BDP (mean 500 ug daily). 
Simons et al. (40) conducted a cross-sectional study in 
95 young patients (median age 13.8 years) taking 
inhaled BDP or budesonide (300-2000 yg daily for a 
median of 5 yr). No PSCCs were found and the 
authors concluded that routine screening for PSCCs in 
this patient population was not warranted. 
A population-based, cross-sectional study of the 
prevalence of cataracts in 3654 people (aged 49-97 
years; mean age 65 years) was conducted in Australia 
(41). In the 370 subjects reported using inhaled BDP, 
either currently or previously, there Gas a higher 
prevalence of PSCCs predominantly in subjects with a 
lifetime dose of >2000 mg. Adjusting for the use of 
systemic corticosteroids and other potential con- 
founding factors had little effect on the magnitude of 
this association. The association with PSCCs was less 
marked when the analysis was restricted to subjects 
who had never used systemic corticosteroids. This 
study was conducted in 1992 and 1993, and because 
budesonide was approved for use in Australia in late 
199 1 BDP was the only inhaled corticosteroid used for 
any extended period. However, there is no reason to 
suspect that the effect of budesonide would be any 
different from that of BDP 
Conclusions 
The majority of comparative studies suggest that low 
to medium dosages (2400 ug day-i) of inhaled BDP 
and budesonide have no effect on adrenal function in 
adults and children. Two non-comparative studies 
examining long-term use (21 yr) of inhaled BDP and 
budesonide in children support this conclusion. High 
dosages of BDP and budesonide (~1500 ug day-1 in 
adults and >400 ug day-1 in children) do appear to 
have an effect on adrenal function, but there is consid- 
erable interindividual variation. Moreover, the clinical 
significance of this effect is not known (for example, 
whether adrenal suppression will correlate with side- 
effects in other tissues). There is no convincing evi- 
dence of a statistically significant difference in effect 
on adrenal function between BDP and budesonide, 
but in many studies BDP appears to have greater HPA 
axis suppression than budesonide on a microgram- 
for-microgram basis (Table 1). 
Skin thinning and bruising may be associated with 
the use of high dosages of inhaled steroids, especially 
in older subjects. However, individuals receiving such 
therapy often have a history of oral steroid treatment 
which is a confounding factor. Further studies are 
warranted to determine whether easy bruising corre- 
lates with adrenal suppression. It would appear to be 
prudent to be alert to easy bruising in elderly patients 
receiving long-term (years) high-dose inhaled 
steroids. There are no comparative data with respect 
to the relative incidence of skin changes with 
budesonide and BDP 
For some time now it has been known that systemic 
corticosteroids can cause PSCCs. However, it would 
now appear that long-term, high-dose (cumulative life- 
time dose >2000 mg) inhaled corticosteroid treatment 
is also associated with an increased prevalence of 
PSCCs in adult patients. However, multiple risk fac- 
tors are associated with the formation of cataracts, 
including use of inhaled or systemic steroids, smoking, 
diabetes mellitus, hypertension, sun exposure and age. 
The risk:benefit ratio for inhaled corticosteroids is 
highly favourable compared with oral corticosteroids. 
As with any drug, in order to minimise the potential 
for adverse effects, the lowest dose of an inhaled 
corticosteroid that achieves the desired effect should 
be used. 
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